Asia Pacific Animal Parasiticides Market

The Asia Pacific animal parasiticides market is projected to reach USD 3.20 billion by 2031 from USD 2.26 billion in 2026, growing at a CAGR of 7.2%.

The Asia Pacific animal parasiticides market is driven by the increasing incidence of parasitic infestations and vector-borne diseases among both livestock and companion animals, especially in tropical and subtropical regions. The growing focus on preventive animal healthcare, along with demand for long-lasting parasiticides and easier administration, is driving the adoption of advanced delivery systems, such as sustained-release injectables, improved topical treatments, oral solutions, and precision dosing devices. A rise in the adoption of digital farm management software, parasite monitoring software, and smart animal healthcare software is further fueling innovation and targeted parasiticides. In fact, changing veterinary regulatory landscapes, a rise in regional manufacturing capacity, growing adoption of home- and farm-based treatment approaches, and closer partnerships among animal healthcare firms, regional manufacturers, and veterinary CDMOs are fast-tracking overall growth of the Asia Pacific animal parasiticides market.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the Asia Pacific animal parasiticides market are Zoetis Services LLC (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Vetoquinol (France), Norbrook (UK), Phibro Animal Health Corporation (US), and Bimeda Corporate (Ireland), among others. All these have adopted various growth strategies, including organic and inorganic approaches such as product launches/development, partnerships, and expansion into new markets. All these are geared at boosting their market share and enhancing diversification.

In July 2025, Merck & Co., Inc. received US FDA approval for BRAVECTO QUANTUM, a once-yearly extended-release injectable that protects dogs against fleas and ticks.
In April 2025, Zoetis Services LLC announced that the US FDA approved an expanded indication for Simparica Trio, a combination parasiticide for dogs that helps prevent flea tapeworm infections.

Zoetis Services LLC offers a diversified portfolio of parasiticides, vaccines, anti-infectives, diagnostic products, and Animal Health Services, an Animal Health company with operations in more than 100 countries and developing sales in Asia Pacific. The company offers products for both endoparasitic prevention and treatment, such as Simparica and Simparica Trio, plus additional ecto- and endoparasiticides for parasitic control in cattle, swine, poultry, and even sheep and aquatic species. In developing the parasiticides market in the Asia Pacific region, Zoetis has facilitated local manufacturing capabilities, R&D activities, and strategic partnerships with distributors that help the company address the varied nature and government regulations regarding parasites across countries such as China, India, Japan, Australia, and Southeast Asia.

Merck & Co., Inc. is a global healthcare company with two primary business segments: Pharmaceuticals and Animal Health. The Animal Health division comprises a wide range of parasiticides, vaccines, pharmaceuticals, and health management solutions for both companion animals and livestock. The Animal Health business is primarily geared toward the two core segments: Companion Animal and Livestock, which together represent the basis of Merck’s parasiticide strategy. The Companion Animal segment offers top ecto- and endoparasiticides, including BRAVECTO and BRAVECTO PLUS, whereas the Livestock segment provides parasite control solutions for cattle, poultry, swine, and aquaculture through systemic and topical parasiticides. In the Asia Pacific region, Merck Animal Health maintains a strong presence through local manufacturing sites, R&D capabilities, and commercial operations across major markets.

Market Ranking

The top five companies in Asia Pacific animal parasiticides formulation are Zoetis Services LLC (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), and Virbac (France). Zoetis?‍?‌‍?‍‌?‍?‌‍?‍‌ Services LLC is the leader in the animal parasiticides market with an extensive portfolio of ecto- and endoparasiticides for companion animals and livestock, backed by robust global manufacturing and a rising presence in Asia Pacific. Merck & Co., Inc. consolidates its position through flagship brands, such as BRAVECTO and EXZOLT, supported by expertise in long-acting formulations and large-scale production. Boehringer Ingelheim International GmbH continues to have a strong position with a diversified parasiticide portfolio supported by deep R&D and integrated manufacturing. Elanco is expanding its reach through combination therapies and lifecycle management for companion and production animals. Virbac is dedicated to the production of parasiticides for companion animals and offers proprietary, long-acting topical solutions, supported by specialized R&D and manufacturing.

Related Reports:

Asia Pacific Animal Parasiticides Market by Type [Ectoparasiticides (Pour-ons & Spot-ons, Dips), Endoparasiticides (Oral liquids, Injectables, Feed Additives), Endectocides], Animal Type (Companion Animals, Livestock), End User - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com